# Repligen Corporation – Consensus ‘buy’ rating and 27.1% Upside Potential

- Link: https://www.directorstalkinterviews.com/repligen-corporation-consensus-buy-rating-and-27.1-upside-potential/4121152380
- Published: 2024-04-19T13:32:00+01:00
- Author: Charlotte Edwards

**Repligen Corporation** with ticker code (RGEN) now have 11 confirmed analysts 
covering the stock with the consensus suggesting a rating of ‘buy’. The range between
the high target price and low target price is between $225.00 and $160.00 calculating
the average target price we see $204.62. Now with the previous closing price of 
$160.98 and the analysts are correct then we can expect a percentage increase in
value of 27.1%. The day 50 moving average is $189.35 while the 200 day moving average
is $169.97. The company has a market cap of 8.77B. The stock price is currently 
at: $157.06 USD

 The potential market cap would be $11,147,448,914 based on the market consensus.

The company has a dividend yield of 5.38%. Other points of data to note are a P/
E ratio of 212.24, revenue per share of $11.46 and a 1.31% return on assets.

Repligen Corporation is a life sciences company, which develops and commercializes
bioprocessing technologies and systems that rises flexibility in the process of 
manufacturing biological drugs. The Company’s bioprocessing business consist of 
four franchises, filtration; chromatography; process analytics; and proteins. The
Filtration products are used in process development and process scale production.
The Chromatography franchise includes products used in downstream purification, 
development, and manufacturing of biological drugs. The Process Analytics products
allow end-users to make in-line absorbance measurements allowing for the determination
of protein concentration in filtration, chromatography formulation and fill-finish
applications. The Proteins franchise is represented by its Protein A affinity ligands,
which are a critical component of Protein A chromatography resins used in downstream
purification of virtually all monoclonal antibody (mAb) based drugs on the market.

Share on:
